Share class: Laboratorios Farmaceuticos Rovi, S.A.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A151,235,76216,208,105 ( 31.63 %) 86,264 ( 0.1684 %) 31.63 %

Major shareholders: Laboratorios Farmaceuticos Rovi, S.A.

NameStocks%Valuation
Norbel Inversiones SL
58.19 %
29,812,040 58.19 % 2 063 M €
Indumenta Pueri SL
9.839 %
5,041,331 9.839 % 349 M €
Santander Private Banking Gestion SA SGIIC
1.154 %
591,115 1.154 % 41 M €
Invesco Asset Management Ltd.
0.978 %
501,085 0.978 % 35 M €
Shareholder Value Management AG
0.8396 %
430,155 0.8396 % 30 M €
BN & Partners Capital AG
0.7137 %
365,686 0.7137 % 25 M €
Financière de l'Échiquier SA
0.5994 %
307,085 0.5994 % 21 M €
Bestinver Gestión SA SGIIC
0.5548 %
284,269 0.5548 % 20 M €
Muza Gestion de Activos SGIIC SA
0.4759 %
243,826 0.4759 % 17 M €
BNP Paribas Asset Management Belgium SA
0.464 %
237,749 0.464 % 16 M €
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Others68.02%
Institutional10.04%
Laboratorios Farmaceúticos Rovi SA0.17%
Unknown21.77%

Based on 1000 largest holdings

Geographical origin of shareholders

Spain
73.41%
Germany
1.69%
United Kingdom
1.14%
France
0.75%
Belgium
0.47%
Netherlands
0.21%
Luxembourg
0.21%
Italy
0.17%
Finland
0.16%
United States
0.01%
Mexico
0.01%

Based on 1000 largest holdings

Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!